دورية أكاديمية
When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
| العنوان: | When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases |
|---|---|
| المؤلفون: | Kobayashi, Masatake, Girerd, Nicolas, Zannad, Faiez |
| المساهمون: | Tokyo Medical University, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P), Centre d'investigation clinique Nancy (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy, French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ) |
| المصدر: | ISSN: 0931-0509. |
| بيانات النشر: | HAL CCSD Oxford University Press |
| سنة النشر: | 2024 |
| المجموعة: | Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe) |
| مصطلحات موضوعية: | [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; Abstract Kidney disease frequently coexists with cardiovascular diseases, and this dual presence significantly amplifies the risk of adverse clinical outcomes. Shared pathophysiological mechanisms and common cardiovascular risk factors contribute to the increased expression of mineralocorticoid receptors, which in turn can drive the progression of chronic cardiovascular-kidney disorder. The steroidal mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone have demonstrated the efficacy in improving patient outcomes in cases of heart failure with reduced ejection fraction or those after a myocardial infarction, but have limited value in patients with chronic kidney disease. The non-steroidal MRA finerenone has now established itself as a foundational guideline-recommended therapy in patients with diabetic kidney disease. To date, these pharmacological agents have been developed in distinct patient populations. The consequences of their distinct pharmacological profiles necessitate further consideration. They have not undergone testing across the entire spectrum of cardiorenal scenarios, and the evidence base is currently being complemented with ongoing trials. In this review, we aim to synthesize the existing body of evidence and chart the future trajectory for the use of spironolactone, eplerenone and finerenone in improving clinical outcomes across the diverse spectrum of cardiorenal diseases. By consolidating the current state of knowledge, we seek to provide valuable insights for informed decision-making in the management of patients with these complex and interconnected conditions. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-04384731; https://hal.univ-lorraine.fr/hal-04384731Test; https://hal.univ-lorraine.fr/hal-04384731/documentTest; https://hal.univ-lorraine.fr/hal-04384731/file/mra_CCVKD_paper.pdfTest |
| DOI: | 10.1093/ndt/gfae004 |
| الإتاحة: | https://doi.org/10.1093/ndt/gfae004Test https://hal.univ-lorraine.fr/hal-04384731Test https://hal.univ-lorraine.fr/hal-04384731/documentTest https://hal.univ-lorraine.fr/hal-04384731/file/mra_CCVKD_paper.pdfTest |
| رقم الانضمام: | edsbas.F7664086 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ndt/gfae004 |
|---|